Use of methotrexate in sarcoid-associated optic neuropathy

Ophthalmology

Volumn 110, Issue 3, 2003, Pages 559-563

  Maust, Heather A ^a   Foroozan, Rod ^a   Sergott, Robert C ^a   Niazi, Sultan ^b   Weibel, Sandra ^b   Savino, Peter J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ALOPECIA; ANXIETY DISORDER; ARTICLE; AUTOMATION; BIOPSY TECHNIQUE; CASE REPORT; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; HYPERGLYCEMIA; INSOMNIA; LABORATORY DIAGNOSIS; LEUKOPENIA; MOOD DISORDER; OPTIC NERVE DISEASE; PERIMETRY; POLYURIA; PRIORITY JOURNAL; REDUCTION; SARCOIDOSIS; STEROID THERAPY; VISUAL ACUITY; VISUAL FIELD DEFECT; WEIGHT GAIN;

EID: 0037370595     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01889-4     Document Type: Article

References (25)

1. Soriano FG, Caramelli P, Nitrini R, Rocha AS. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad Med J 1990;66:142-3.
2. Newman LS, Rose CS, Maier LA. Sarcoidosis [published erratum appears in N Engl J Med 1997;337:139]. N Engl J Med 1997;336:1223-34.
3. Jordan DR, Anderson RL, Nerad JA, et al. Optic nerve involvement as the initial manifestation of sarcoidosis. Can J Ophthalmol 1988;23:232-7.
4. Frohman LP, Grigorian R, Bielory L. Neuro-ophthalmic manifestations of sarcoidosis: clinical spectrum, evaluation, and management. J Neuroophthalmol 2001;21:132-7.
5. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol 2000;84:110-6.
6. Lester RS, Knowles SR, Shear NH. The risks of systemic corticosteroid use. Dermatol Clin 1998;16:277-86.
7. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997;111:732-43.
8. Hillson JL, Furst DE. Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Practical issues in treatment and design. Rheum Dis Clin North Am 1997;23:757-73.
9. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997;36:1196-204.
10. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999;54:742-6.
11. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
12. Boffa MJ, Chalmers RJG. Methotrexate for psoriasis. Clin Exp Dermatol 1996;21:399-408.
13. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99:1419-23.
14. Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol 1969;67:383-7.
15. Shetty AK, Zganjar BE, Ellis GS Jr, et al. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus 1999;36:125-8.
16. Samson CM, Waheed N, Baltatzis S, Foster S. Methotrexate therapy for chronic non-infectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001;108:1134-9.
17. Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001;85:1220-4.
18. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-55.
19. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:60-6.
20. Kaye O, Palazzo E, Grossin M, et al. Low-dose methotrexate. an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995;34:642-4.
21. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999;106:111-8.
22. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995;155:846-51.
23. Weinblatt ME, Maier AL. Longterm experience with low dose weekly methotrexate in rheumatoid arthritis. J Rheumatol 1990;17(Suppl 22):33-8.
24. Sandoval DM, Alarc6n GS, Morgan SL. Adverse events in methotrexate-treated rheumatoid arthritis patients. Br J Rheumatol 1995;34(Suppl 2):49-56.
25. McKendry RJR. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997;23:939-51.